SCHEMBL3387044

SCHEMBL3387044

N#Cc1ccc(/C(=C\c2ccccc2)C(=O)O)cc1

nearest known ligand 0.68

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
AKR1C1 Q04828 3/20 0.68
AKR1C3 P42330 4/20 0.56
KMT2A Q03164 5/20 0.55
ALDH1A1 P00352 5/20 0.55
KDM4E B2RXH2 3/20 0.55
PKM P14618 1/20 0.55
ATM Q13315 1/20 0.55
MEN1 O00255 4/20 0.53
POLB P06746 2/20 0.53
MAPT P10636 3/20 0.51
RAB9A P51151 1/20 0.51
AKR1C2 P52895 2/20 0.50
LMNA P02545 2/20 0.50
L3MBTL1 Q9Y468 1/20 0.50
PTGS2 P35354 2/20 0.49
HTT P42858 2/20 0.46
HPGD P15428 1/20 0.46
MAPK1 P28482 1/20 0.46
CA1 P00915 2/20 0.46
CA2 P00918 2/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3387047 1.00 AKR1C1 (0.68) AKR1C1AKR1C3KMT2AALDH1A1KDM4E
SCHEMBL16968140 0.87 PTGS2 (0.58) AKR1C1AKR1C3KMT2AALDH1A1KDM4E
SCHEMBL16968143 0.87 PTGS2 (0.58) AKR1C1AKR1C3KMT2AALDH1A1KDM4E
SCHEMBL622906 0.83 AKR1C1 (0.62) AKR1C1AKR1C3KMT2AALDH1A1KDM4E
SCHEMBL622907 0.83 AKR1C1 (0.62) AKR1C1AKR1C3KMT2AALDH1A1KDM4E
SCHEMBL181529 0.82 AKR1C1 (1.00) AKR1C1AKR1C3KMT2AALDH1A1KDM4E
SCHEMBL290469 0.82 AKR1C1 (1.00) AKR1C1AKR1C3KMT2AALDH1A1KDM4E
SCHEMBL39275 0.82 AKR1C1 (1.00) AKR1C1AKR1C3KMT2AALDH1A1KDM4E
SCHEMBL9298399 0.80 AKR1C1 (0.81) AKR1C1AKR1C3KMT2AALDH1A1KDM4E
SCHEMBL1416571 0.80 AKR1C1 (0.81) AKR1C1AKR1C3KMT2AALDH1A1KDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2168962-A2 PHENYLACETAMIDES AND THEIR USE AS GLUCOKINASE MODULATORS Prosidion Limited (GB) 2010-03-31 EP disclosed
US-7582632-B2 Tri(cyclo) substituted amide compounds PROSIDION LIMITED (GB) 2009-09-01 US disclosed
US-7582632-B2 Tri(cyclo) substituted amide compounds PROSIDION LIMITED (GB) 2009-09-01 US disclosed
US-7582632-B2 Tri(cyclo) substituted amide compounds PROSIDION LIMITED (GB) 2009-09-01 US disclosed
US-20070281946-A1 TRI(CYCLO) SUBSTITUTED AMIDE COMPOUNDS OSI PHARMACEUTICALS, INC. 2007-12-06 US disclosed
US-20070281946-A1 TRI(CYCLO) SUBSTITUTED AMIDE COMPOUNDS OSI PHARMACEUTICALS, INC. 2007-12-06 US disclosed
US-20070281946-A1 TRI(CYCLO) SUBSTITUTED AMIDE COMPOUNDS OSI PHARMACEUTICALS, INC. 2007-12-06 US disclosed
US-7214681-B2 Tri(cyclo) substituted amide compounds PROSIDION LIMITED (GB) 2007-05-08 US disclosed
US-7214681-B2 Tri(cyclo) substituted amide compounds PROSIDION LIMITED (GB) 2007-05-08 US disclosed
US-7214681-B2 Tri(cyclo) substituted amide compounds PROSIDION LIMITED (GB) 2007-05-08 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070281946-A1 TRI(CYCLO) SUBSTITUTED AMIDE COMPOUNDS IAPP, GPR119, SLC5A1 AKR1C1 782/4885AKR1C3 921/4885KMT2A 3964/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.